NOVARTIS AND UNIVERSITY OF PENNSYLVANIA
different functional areas contained within the facility, such as vaccine development, assay development, and correlative studies of blood and other
bio specimens, to examine how trial participants respond to the therapies
EXCITING NEW THERAPIES
In addition to continued trials in CLL, Penn has engineered T cell trials underway for other types of leukemia, as well as lymphoma, mesothelioma,
myeloma, and neuroblastoma.
In 2014, the US Food and Drug Administration awarded breakthrough
therapy designation to CTL019, an investigational CAR therapy for the
treatment of relapsed and refractory adult and pediatric acute lymphoblastic leukemia. CTL019 is the first personalized cellular therapy for the
treatment of cancer to receive this important classification.
Pioneered by Penn Medicine, this new application first removes a patient’s T cells, then genetically reprograms them in the CACT’s clinical cell
and vaccine production facility. After being infused back into the patient,
these hunter cells both multiply and attack, targeting tumor cells that express the DCD19 protein. Tests reveal that each single engineered cell can
grow into an army of more than 10,000.
Ultimately, the CACT’s objective is to develop new treatment options for
life-threatening diseases. “This new joint center is testimony to the power
that comes from merging academic discovery and the generation of new
medicines,” says Mark Fishman, President of Novartis Institutes for BioMedical Research. ‹›
KEY PROJECT PARTICIPANTS
MANUFAC TURER/OWNER Penn Medicine: University of Pennsylvania Health System
ENGINEER/ARCHITEC T (A&E) CannonDesign
225 North Michigan Ave.
Chicago, Illinois 60601 United States
833 Chestnut St.
Philadelphia, Pennsylvania 19107 United States
CONSTRUC TION MANAGER L. F. Driscoll Company, LLC
3600 Civic Center Blvd.
Philadelphia, Pennsylvania 19104 United States
MAJOR EQUIPMENT SUPPLIER AES Clean Technology, Inc.
422 Stump Rd.
Montgomeryville, Pennsylvania 18936 United States